Psychopathological characteristics and social functioning of the schizophrenic patients with the T allele of the MTHFR677C&amp;gt;T polymorphism

Zhilyaeva T.V.; Sergeeva A.V.; Blagonravova A.S.; Kasimova L.N.

doi:https://doi.org/10.17116/jnevro20161161115-11

Zhilyaeva T.V.

Nizhegorodskaja gosudarstvennaja meditsinskaja akademija, Nizhnij Novgorod, Rossija

ORCID: 0000-0001-6155-1007

Sergeeva A.V.

Nizhegorodskaja gosudarstvennaja meditsinskaja akademija, Nizhnij Novgorod, Rossija

Blagonravova A.S.

Nizhegorodskaja gosudarstvennaja meditsinskaja akademija, Nizhnij Novgorod, Rossija

Kasimova L.N.

Nizhegorodskaja gosudarstvennaja meditsinskaja akademija, Nizhnij Novgorod, Rossija

Psychopathological characteristics and social functioning of the schizophrenic patients with the T allele of the MTHFR677C>T polymorphism

Authors:

Zhilyaeva T.V., Sergeeva A.V., Blagonravova A.S., Kasimova L.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(11): 5‑11

DOI: 10.17116/jnevro20161161115-11

Read: 1590 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Zhilyaeva TV, Sergeeva AV, Blagonravova AS, Kasimova LN. Psychopathological characteristics and social functioning of the schizophrenic patients with the T allele of the MTHFR677C>T polymorphism. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(11):5‑11. (In Russ.)
https://doi.org/10.17116/jnevro20161161115-11

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

Abstract:

Objective. To compare the severity of psychopathological symptoms and characteristics of personal and social functioning in patients with schizophrenia, carriers of different alleles of the MTHFR677C>T polymorphism. Material and methods. One hundred and fifty patients diagnosed with schizophrenia were genotyped for the MTHFR677C>T polymorphism, some of them were examined using psychometric scales and tests (PANSS, SANS, PSP, CDSS, a battery of cognitive tests etc). Results and conclusion. Patients with the MTHFR677T variant had greater severity of negative symptoms regardless of psychometric instruments used in the study, greater severity of schizophrenia disorder in whole measured with the PANSS General psychopathological symptoms subscale, higher scores on the PANSS cognitive cluster and lower levels of personal and social functioning measured with the PSP compared to the patients with the MTHFR677CС genotype. The results of psychometric testing are in line with significant differences of MTHFR677T allele carriers from those with the MTHFR677CС genotype in the number of disable patients and the use of different types of psychiatric services. The differences were not related to sex, age, illness duration and depressive symptoms measured with CDSS and PANSS «depression/anxiety» factor.

Keywords:

schizophrenia

MTHFR677C>T polymorphism

PANSS

SANS

PSP

Authors:

Zhilyaeva T.V.

Nizhegorodskaja gosudarstvennaja meditsinskaja akademija, Nizhnij Novgorod, Rossija

ORCID: 0000-0001-6155-1007

Sergeeva A.V.

Nizhegorodskaja gosudarstvennaja meditsinskaja akademija, Nizhnij Novgorod, Rossija

Blagonravova A.S.

Nizhegorodskaja gosudarstvennaja meditsinskaja akademija, Nizhnij Novgorod, Rossija

Kasimova L.N.

Nizhegorodskaja gosudarstvennaja meditsinskaja akademija, Nizhnij Novgorod, Rossija

Close metadata

References:

Muntjewerff J-W, Blom HJ. Aberrant folate status in schizophrenic patients: What is the evidence? Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2005;29(7):1133-1139. doi: 10.1016/j.pnpbp.2005.06.024
Zhiljaeva TV. Narushenija odnouglerodnogo metabolizma pri shizofrenii. Psihiatrija i psihofarmakoterapija. 2012;14(6):41-46. (In Russ.).
Zhiljaeva TV. Narushenija obmena folatov v svete dizontogeneticheskoj gipotezy jetiologii shizofrenii. Social'naja i klinicheskaja psihiatrija. 2012;22(1):88-94. (In Russ.).
Zintzaras E. C677T and A1298C methylenetetrahydrofolate reductase gene polymorphisms in schizophrenia, bipolar disorder and depression: a meta-analysis of genetic association studies. Psychiatr Genet. 2006;16(3):105-115. doi: 10.1097/01.ypg.0000199444.77291.e2
Muntjewerff JW, Kahn RS, Blom HJ, den Heijer M. Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Mol Psychiatry. 2006;11(2):143-149. doi: 10.1038/sj.mp.4001746
Gilbody S, Lewis S, Lightfoot T. Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: a HuGE review. Am J Epidemiol. 2007;165(1):1-13. doi: 10.1093/aje/kwj347
Regland B, Germgård T, Gottfries CG, Grenfeldt B, Koch-Schmidt AC. Homozygous thermolabile methylenetetrahydrofolate reductase in schizophrenia-like psychosis. J Neural Transm. 1997;104(8-9):931-941. doi: 10.1007/bf01285561
Allen NC, Bagade S, McQueen MB, Ioannidis JPA, Kavvoura FK, Khoury MJ, Bertram L et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nature. 2008;40(7):827-834. doi: 10.1038/ng.171
Roffman JL, Weiss AP, Purcell S, Caffalette CA, Freudenreich O, Henderson DC, Goff DC et al. Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia. Biol Psychiatry. 2008;63(1):42-48. doi: 10.1016/j.biopsych.2006.12.017
Roffman JL, Brohawn DG, Nitenson AZ, Macklin EA, Smoller JW, Goff DC. Genetic Variation Throughout the Folate Metabolic Pathway Influences Negative Symptom Severity in Schizophrenia. Schizophr Bull. 2011;39(2):330-338. doi: 10.1093/schbul/sbr150
Petronijević ND, Radonjić NV, Ivković MD, Marinković D, Piperski VD, Duricić BM, Paunović VR. Plasma homocysteine levels in young male patients in the exacerbation and remission phase of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(8):1921-1926. doi: 10.1016/j.pnpbp.2008.09.009
Roffman JL, Weiss AP, Deckersbach T, Freudenreich O, Henderson DC, Purcell S, Wong DH, Halsted CH, Goff DC. Effects of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism on executive function in schizophrenia. Schizophr Res. 2007;92(1-3):181-188. doi: 10.1016/j.schres.2007.01.003
Kim TH, Moon SW. Serum Homocysteine and Folate Levels in Korean Schizophrenic Patients. Psychiatry Investig. 2011;8(2):134-140. doi: 10.4306/pi.2011.8.2.134
Jönsson EG, Larsson K, Vares M, Hansen T, Wang AG, Djurovic S, Hall H et al. Two methylenetetrahydrofolate reductase gene (MTHFR) polymorphisms, schizophrenia and bipolar disorder: an association study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 147B(6):976-982. doi: 10.1002/ajmg.b.30671
Yoshimi A, Aleksic B, Kawamura Y, Takahashi N, Yamada S, Usui H, Ozaki N et al. Gene-wide association study between the methylenetetrahydrofolate reductase gene (MTHFR) and schizophrenia in the Japanese population, with an updated meta-analysis on currently available data. Schizophr Res. 2010;124(1-3):216-222. doi: 10.1016/j.schres.2010.07.011
Hill M, Shannahan K, Jasinski S, Macklin EA, Raeke L, Roffman JL, Goff DC. Folate supplementation in schizophrenia: A possible role for MTHFR genotype. Schizophr Res. 2011;127(1-3):41-45. doi: 10.1016/j.schres.2010.12.006
Roffman JL, Lamberti JS, Achtyes E, Macklin EA, Galendez GC, Raeke LH, Goff DC et al. Randomized Multicenter Investigation of Folate Plus Vitamin B 12 Supplementation in Schizophrenia. JAMA Psychiatry. 2013;70(5):481. doi: 10.1001/jamapsychiatry.2013.900
Levine J, Stahl Z, Sela BA, Ruderman V, Shumaico O, Babushkin I, Osher Y, Bersudsky Y, Belmaker RH. Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biol Psychiatry. 2006;60(3):265-269. doi: 10.1016/j.biopsych.2005.10.009
Zhiljaeva TV, Sergeeva AV, Kasimova LN, Blagonravova AS. Dinamika kognitivnyh funkcij na fone augmentacii terapii folatami u pacientov s shizofreniej, nositelej polimorfizma gena MTHFR677C>T: pilotnoe issledovanie. Sovremennye tehnologii v medicine. 2015;7(4):147-153. doi: 10.17691/stm2015.7.4.20 (In Russ.).
Sarkisjan GR, Gurovich IJa, Kif RS. Normativnye dannye dlja rossijskoj populjacii i standartizacija shkaly «Kratkaja ocenka kognitivnyh funkcij u pacientov s shizofreniej» (BACS). Social'naja i klinicheskaja psihiatrija. 2010;20(3):13-19. (In Russ.).
Lindenmayer JP, Grochowski S, Meibach R. Five factor model of schizophrenia: Replication across samples. Schizophrenia Research. 1993;9(2-3):103. doi: 10.1016/0920-9964(93)90122-y
Mosolov SN. Shkaly psihometricheskoj ocenki shizofrenii i koncepcija pozitivnyh i negativnyh rasstrojstv. M.: Novyj cvet; 2001. (In Russ.).
Addington J, Addington D, Maticka-Tyndale E. Cognitive functioning and positive and negative symptoms of schizophrenia. Schizophrenia Research. 1991;5(2):123-134. doi: 10.1016/0920-9964(91)90039-t
Bagney A, Dompablo M, Santabárbara J, Moreno-Ortega M, Lobo A, Jimenez-Arriero M-A, Rodriguez-Jimenez R et al. Are negative symptoms really related to cognition in schizophrenia? Psychiatry Research. 2015;230(2):377-382. doi: 10.1016/j.psychres.2015.09.022
Lipton SA, Kim W-K, Choi Y-B, Kumar S, D’Emilia DM, Rayudu PV, Stamler JS et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proceedings of the National Academy of Sciences. 1997;94(11):5923-5928. doi: 10.1073/pnas.94.11.5923
Shi Q. L-Homocysteine Sulfinic Acid and Other Acidic Homocysteine Derivatives Are Potent and Selective Metabotropic Glutamate Receptor Agonists. Journal of Pharmacology and Experimental Therapeutics. 2003;305(1):131-142. doi: 10.1124/jpet.102.047092
Ho PI, Ortiz D, Rogers E, Shea TB. Multiple aspects of homocysteine neurotoxicity: Glutamate excitotoxicity, kinase hyperactivation and DNA damage. Journal of Neuroscience Research. 2002;70(5):694-702. doi: 10.1002/jnr.10416